Biomarker Approach to the Detection and Cardioprotective Strategies During Anthracycline Chemotherapy

Heart Failure Clinics

Volumn 7, Issue 3, 2011, Pages 323-331

  Ky, Bonnie ^a,b   Carver, Joseph R ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Anthracyclines; Biomarker; Cardioprotective agents; Chemotherapy cardiotoxicity

Indexed keywords

ACETYLCYSTEINE; AMIFOSTINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATRIAL NATRIURETIC FACTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARNITINE; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXORUBICIN; ENALAPRIL; LIPID PEROXIDE; PLACEBO; PROBUCOL; RAZOXANE; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; TROPONIN T; VALSARTAN;

ACUTE LYMPHOCYTIC LEUKEMIA; BREAST CANCER; CANCER CHEMOTHERAPY; CARDIOTOXICITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; ECHOCARDIOGRAPHY; EXERCISE TEST; FOLLOW UP; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART PROTECTION; HIGH RISK PATIENT; HUMAN; MULTIPLE CYCLE TREATMENT; OXIDATIVE STRESS; PREDICTIVE VALUE; PROGRESSION FREE SURVIVAL; REVIEW; SIDE EFFECT; SYSTOLIC DYSFUNCTION; TREATMENT RESPONSE; VASCULAR RESISTANCE;

ADULT; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; BIOMARKERS, PHARMACOLOGICAL; CARDIOTONIC AGENTS; CARDIOTOXINS; CHILD; DRUG MONITORING; EARLY DIAGNOSIS; HEART; HEART DISEASES; HUMANS; META-ANALYSIS AS TOPIC; NEOPLASMS; RISK FACTORS;

EID: 79960258058     PISSN: 15517136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hfc.2011.03.002     Document Type: Review

References (67)

1. Felker G.M., Thompson R.E., Hare J.M., et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 2000, 342(15):1077-1084.
2. Yeh E.T., Tong A.T., Lenihan D.J., et al. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation 2004, 109(25):3122-3131.
3. Altena R., Perik P.J., van Veldhuisen D.J., et al. Cardiovascular toxicity caused by cancer treatment: strategies for early detection. Lancet Oncol 2009, 10(4):391-399.
4. Chen B., Peng X., Pentassuglia L., et al. Molecular and cellular mechanisms of anthracycline cardiotoxicity. Cardiovasc Toxicol 2007, 7(2):114-121.
5. Jones L.W., Haykowsky M.J., Swartz J.J., et al. Early breast cancer therapy and cardiovascular injury. J Am Coll Cardiol 2007, 50(15):1435-1441.
6. Gianni L., Herman E.H., Lipshultz S.E., et al. Anthracycline cardiotoxicity: from bench to bedside. J Clin Oncol 2008, 26(22):3777-3784.
7. Tokarska-Schlattner M., Zaugg M., Zuppinger C., et al. New insights into doxorubicin-induced cardiotoxicity: the critical role of cellular energetics. J Mol Cell Cardiol 2006, 41(3):389-405.
8. Zuppinger C., Timolati F., Suter T.M. Pathophysiology and diagnosis of cancer drug induced cardiomyopathy. Cardiovasc Toxicol 2007, 7(2):61-66.
9. Lim C.C., Zuppinger C., Guo X., et al. Anthracyclines induce calpain-dependent titin proteolysis and necrosis in cardiomyocytes. J Biol Chem 2004, 279(9):8290-8299.
10. Jeyaseelan R., Poizat C., Wu H.Y., et al. Molecular mechanisms of doxorubicin-induced cardiomyopathy. Selective suppression of Reiske iron-sulfur protein, ADP/ATP translocase, and phosphofructokinase genes is associated with ATP depletion in rat cardiomyocytes. J Biol Chem 1997, 272(9):5828-5832.
11. Slamon D.J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344(11):783-792.
12. De Angelis A., Piegari E., Cappetta D., et al. Anthracycline cardiomyopathy is mediated by depletion of the cardiac stem cell pool and is rescued by restoration of progenitor cell function. Circulation 2010, 121(2):276-292.
13. Huang C., Zhang X., Ramil J.M., et al. Juvenile exposure to anthracyclines impairs cardiac progenitor cell function and vascularization resulting in greater susceptibility to stress-induced myocardial injury in adult mice. Circulation 2010, 121(5):675-683.
14. Cardinale D., Colombo A., Cipolla C.M. Prevention and treatment of cardiomyopathy and heart failure in patients receiving cancer chemotherapy. Curr Treat Options Cardiovasc Med 2008, 10(6):486-495.
15. Vasan R.S. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation 2006, 113(19):2335-2362.
16. Morrow D.A., de Lemos J.A. Benchmarks for the assessment of novel cardiovascular biomarkers. Circulation 2007, 115(8):949-952.
17. Braunwald E. Biomarkers in heart failure. N Engl J Med 2008, 358(20):2148-2159.
18. Bryant J., Picot J., Baxter L., et al. Use of cardiac markers to assess the toxic effects of anthracyclines given to children with cancer: a systematic review. Eur J Cancer 2007, 43(13):1959-1966.
19. Lipshultz S.E., Rifai N., Dalton V.M., et al. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med 2004, 351(2):145-153.
20. Hayakawa H., Komada Y., Hirayama M., et al. Plasma levels of natriuretic peptides in relation to doxorubicin-induced cardiotoxicity and cardiac function in children with cancer. Med Pediatr Oncol 2001, 37(1):4-9.
21. Pinarli F.G., Oguz A., Tunaoglu F.S., et al. Late cardiac evaluation of children with solid tumors after anthracycline chemotherapy. Pediatr Blood Cancer 2005, 44(4):370-377.
22. Soker M., Kervancioglu M. Plasma concentrations of NT-pro-BNP and cardiac troponin-I in relation to doxorubicin-induced cardiomyopathy and cardiac function in childhood malignancy. Saudi Med J 2005, 26(8):1197-1202.
23. Yaris N., Ceviz N., Coskun T., et al. Serum carnitine levels during the doxorubicin therapy. Its role in cardiotoxicity. J Exp Clin Cancer Res 2002, 21(2):165-170.
24. Bauch M., Ester A., Kimura B., et al. Atrial natriuretic peptide as a marker for doxorubicin-induced cardiotoxic effects. Cancer 1992, 69(6):1492-1497.
25. Horino N., Kobayashi Y., Usui T. Elevation of lipid peroxide in children treated with a combination of chemotherapeutic agents including doxorubicin. Acta Paediatr Scand 1983, 72(4):549-551.
26. Germanakis I., Anagnostatou N., Kalmanti M. Troponins and natriuretic peptides in the monitoring of anthracycline cardiotoxicity. Pediatr Blood Cancer 2008, 51(3):327-333.
27. Fink F.M., Genser N., Fink C., et al. Cardiac troponin T and creatine kinase MB mass concentrations in children receiving anthracycline chemotherapy. Med Pediatr Oncol 1995, 25(3):185-189.
28. Kismet E., Varan A., Ayabakan C., et al. Serum troponin T levels and echocardiographic evaluation in children treated with doxorubicin. Pediatr Blood Cancer 2004, 42(3):220-224.
29. Kremer L.C., Bastiaansen B.A., Offringa M., et al. Troponin T in the first 24 hours after the administration of chemotherapy and the detection of myocardial damage in children. Eur J Cancer 2002, 38(5):686-689.
30. Mathew P., Suarez W., Kip K., et al. Is there a potential role for serum cardiac troponin I as a marker for myocardial dysfunction in pediatric patients receiving anthracycline-based therapy? A pilot study. Cancer Invest 2001, 19(4):352-359.
31. Aggarwal S., Pettersen M.D., Bhambhani K., et al. B-type natriuretic peptide as a marker for cardiac dysfunction in anthracycline-treated children. Pediatr Blood Cancer 2007, 49(6):812-816.
32. Tikanoja T., Riikonen P., Perkkio M., et al. Serum N-terminal atrial natriuretic peptide (NT-ANP) in the cardiac follow-up in children with cancer. Med Pediatr Oncol 1998, 31(2):73-78.
33. Ekstein S., Nir A., Rein A.J., et al. N-terminal-proB-type natriuretic peptide as a marker for acute anthracycline cardiotoxicity in children. J Pediatr Hematol Oncol 2007, 29(7):440-444.
34. Horacek J.M., Pudil R., Jebavy L., et al. Assessment of anthracycline-induced cardiotoxicity with biochemical markers. Exp Oncol 2007, 29(4):309-313.
35. Horacek J.M., Pudil R., Tichy M., et al. Cardiac troponin I seems to be superior to cardiac troponin T in the early detection of cardiac injury associated with anthracycline treatment. Onkologie 2008, 31(10):559-560.
36. Dodos F., Halbsguth T., Erdmann E., et al. Usefulness of myocardial performance index and biochemical markers for early detection of anthracycline-induced cardiotoxicity in adults. Clin Res Cardiol 2008, 97(5):318-326.
37. Auner H.W., Tinchon C., Brezinschek R.I., et al. Monitoring of cardiac function by serum cardiac troponin T levels, ventricular repolarisation indices, and echocardiography after conditioning with fractionated total body irradiation and high-dose cyclophosphamide. Eur J Haematol 2002, 69(1):1-6.
38. Morandi P., Ruffini P.A., Benvenuto G.M., et al. Serum cardiac troponin I levels and ECG/Echo monitoring in breast cancer patients undergoing high-dose (7 g/m(2)) cyclophosphamide. Bone Marrow Transplant 2001, 28(3):277-282.
39. Kilickap S., Barista I., Akgul E., et al. cTnT can be a useful marker for early detection of anthracycline cardiotoxicity. Ann Oncol 2005, 16(5):798-804.
40. Cardinale D., Sandri M.T., Colombo A., et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 2004, 109(22):2749-2754.
41. Cardinale D., Sandri M.T., Martinoni A., et al. Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy. Ann Oncol 2002, 13(5):710-715.
42. Cardinale D., Sandri M.T., Martinoni A., et al. Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol 2000, 36(2):517-522.
43. Suzuki T., Hayashi D., Yamazaki T., et al. Elevated B-type natriuretic peptide levels after anthracycline administration. Am Heart J 1998, 136(2):362-363.
44. Sandri M.T., Cardinale D., Zorzino L., et al. Minor increases in plasma troponin I predict decreased left ventricular ejection fraction after high-dose chemotherapy. Clin Chem 2003, 49(2):248-252.
45. Knobloch K., Tepe J., Lichtinghagen R., et al. Monitoring of cardiotoxicity during immunotherapy with Herceptin using simultaneous continuous wave Doppler depending on N-terminal pro-brain natriuretic peptide. Clin Med 2007, 7(1):88-89. [author reply: 89].
46. Knobloch K., Tepe J., Rossner D., et al. Combined NT-pro-BNP and CW-Doppler ultrasound cardiac output monitoring (USCOM) in epirubicin and liposomal doxorubicin therapy. Int J Cardiol 2008, 128(3):316-325.
47. Nousiainen T., Jantunen E., Vanninen E., et al. Natriuretic peptides as markers of cardiotoxicity during doxorubicin treatment for non-Hodgkin's lymphoma. Eur J Haematol 1999, 62(2):135-141.
48. Lenihan D.J., Massey M.R., Baysinger K.B., et al. Superior detection of cardiotoxicity during chemotherapy using biomarkers. J Card Fail 2007, 13(Suppl 2):S151.
49. Sandri M.T., Salvatici M., Cardinale D., et al. N-terminal pro-B-type natriuretic peptide after high-dose chemotherapy: a marker predictive of cardiac dysfunction?. Clin Chem 2005, 51(8):1405-1410.
50. Maruvada P., Srivastava S. Joint National Cancer Institute-Food and Drug Administration workshop on research strategies, study designs, and statistical approaches to biomarker validation for cancer diagnosis and detection. Cancer Epidemiol Biomarkers Prev 2006, 15(6):1078-1082.
51. Cardinale D., Colombo A., Sandri M.T., et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 2006, 114(23):2474-2481.
52. Albini A., Pennesi G., Donatelli F., et al. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst 2010, 102(1):14-25.
53. Wouters K.A., Kremer L.C., Miller T.L., et al. Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies. Br J Haematol 2005, 131(5):561-578.
54. Wexler L.H., Andrich M.P., Venzon D., et al. Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin. J Clin Oncol 1996, 14(2):362-372.
55. Swain S.M., Vici P. The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: expert panel review. J Cancer Res Clin Oncol 2004, 130(1):1-7.
56. Swain S.M., Whaley F.S., Gerber M.C., et al. Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy. J Clin Oncol 1997, 15(4):1333-1340.
57. Swain S.M., Whaley F.S., Gerber M.C., et al. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol 1997, 15(4):1318-1332.
58. Hensley M.L., Hagerty K.L., Kewalramani T., et al. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J Clin Oncol 2009, 27(1):127-145.
59. Schuchter L.M., Hensley M.L., Meropol N.J., et al. 2002 Update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2002, 20(12):2895-2903.
60. Lipshultz S.E., Lipsitz S.R., Sallan S.E., et al. Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer. J Clin Oncol 2002, 20(23):4517-4522.
61. Silber J.H., Cnaan A., Clark B.J., et al. Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines. J Clin Oncol 2004, 22(5):820-828.
62. Jessup M., Abraham W.T., Casey D.E., et al. 2009 focused update: ACCF/AHA Guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009, 119(14):1977-2016.
63. Vaynblat M., Shah H.R., Bhaskaran D., et al. Simultaneous angiotensin converting enzyme inhibition moderates ventricular dysfunction caused by doxorubicin. Eur J Heart Fail 2002, 4(5):583-586.
64. Nakamae H., Tsumura K., Terada Y., et al. Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone. Cancer 2005, 104(11):2492-2498.
65. Kalay N., Basar E., Ozdogru I., et al. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol 2006, 48(11):2258-2262.
66. van Dalen E.C., Caron H.N., Dickinson H.O., et al. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev 2008, 2. CD003917.
67. Morris P.G., Hudis C.A. Trastuzumab-related cardiotoxicity following anthracycline-based adjuvant chemotherapy: how worried should we be?. J Clin Oncol 2010, 28(21):3407-3410.